Form 6-K GSK plc For: Oct 30
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GSK plc American Depositary Shares (Each representing two Ordinary Shares) news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- GSK plc (NYSE: GSK) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapseBusiness Wire
- GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- GSK plc (NYSE: GSK) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating.MarketBeat
GSK
Sec Filings
- 12/20/24 - Form 6-K
- 12/20/24 - Form 6-K
- 12/16/24 - Form 6-K
- GSK's page on the SEC website